Research
Neural
Intranasal delivery of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could overcome the limitations of subcutaneous administration for obesity treatment.
Practitioners should consider intranasal delivery methods for improving patient adherence and reducing side effects.
StrongSupportsmedium confidence
Delivering the drug intranasally could overcome these drawbacks.
Why this rating
The abstract discusses a review of existing literature on GLP-1 RAs and their delivery methods.
Source
Intranasal delivery of glucagon-like peptide-1 to the brain for obesity treatment: opportunities and challenges
Tanisha Tabassum Sayka Khan et al. · Expert Opinion on Drug Delivery · 2024
reviewCited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →